Fig. 5

Effect of IL-21 on GVHD and GVT. a Survival curve following MHC-matched allogeneic BMT (C57BL/6 → LP/J) depicting control (syngeneic transplantation) in black, PBS-treated allogeneic BMT in green, and IL-21-treated allogeneic BMT in red. b Weight loss analysis of transplanted animals over 8 weeks post-BMT. Pink area represents a loss of ≥20%. Lost mice are indicated by red arrowheads. c Survival curve following MHC-matched allogeneic BMT depicting PBS-treated allogeneic BMT (WT C57BL/6 → LP/J) in green, IL-21-treated allogeneic BMT (WT C57BL/6 → LP/J) in red, PBS-treated allogeneic BMT (MμMT C57BL/6 → LP/J) in blue, and IL-21-treated allogeneic BMT (MμMT C57BL/6 → LP/J) in black. d Clinical score evaluation for the experiment shown in c. e Survival curve following complete MHC-mismatch allogeneic BMT (C57BL/6 → BALB/c). The color code for the groups is exactly the same one shown in a. f Survival curve for the GVT experiment conducted by challenging transplanted mice with P815 mastocytoma tumor cells. The color code for each group is as follows: green for BMT + PBS, black for BMT + IL-21, blue for BMT + DLI + PBS, and red for BMT + DLI + IL-21. e Representative flow cytometry analysis of IL-21Rα expression on the surface of the P815 tumor cell line. All shown experiments were conducted at least three times with *P < 0.05 and n = 10/group